Dopamine transporter imaging in clinically unclear cases of parkinsonism and the importance of Scans Without Evidence of Dopaminergic Deficit (SWEDDs);Neuroimagem do transportador de dopamina em casos de parkinsonismo clinicamente indefinidos e a importância dos SWEDDs (exames sem evidência de déficit dopaminérgico)

Arquivos de Neuro-Psiquiatria

Volumn 70, Issue 9, 2012, Pages 667-673

  Utiumi, Marco A T ^a   Felício, André C ^b   Borges, Conrado R ^a   Braatz, Vera L ^a   Rezende, Sheyla A S ^a   Munhoz, Renato P ^a   Bressan, Rodrigo A ^b   Ferraz, Henrique B ^b   Teive, Hélio A G ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dopamine transporter; Emission computed; Parkinson disease; Scans without evidence of dopaminergic deficit; Single photon; Tc 99m trodat 1; Tomography

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENSERAZIDE PLUS LEVODOPA; CLONAZEPAM; DOPAMINE TRANSPORTER; FLUNARIZINE; LEVODOPA; LEVOTHYROXINE; PAROXETINE; PIRIBEDIL; ROPINIROLE; SELEGILINE; THYROTROPIN; VENLAFAXINE; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M;

ADULT; ANXIETY; ANXIETY DISORDER; BRADYKINESIA; CASE REPORT; CLINICAL EXAMINATION; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; FAMILY HISTORY; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HAND TREMOR; HUMAN; LACUNAR STROKE; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OBESITY; PANIC; PARKINSONISM; POSTPARTUM THYROIDITIS; RADIOLOGICAL PARAMETERS; REVIEW; SCANS WITHOUT EVIDENCE OF DOPAMINERGIC DEFICIT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROTROPIN BLOOD LEVEL; VERTIGO;

EID: 84866681960     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2012000900004     Document Type: Review

References (20)

1. Litvan I, Bhatia KP, Burn DJ, et al. SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003;18:467-486.
2. National Collaborating Centre for Chronic Conditions. Parkinson's disease: National clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians; 2006.
3. Pankratz ND, Wojcieszek J, Foroud T (Updated July 9, 2009). Parkinson disease overview. In: GeneReviews and GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle, 1997-2011. Available at: http://www.genetest.org. [cited 2011 November 8].
4. Munhoz RP, Werneck LC, Teive HAG. The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. Clin Neurol Neurosur 2010;112:431-435.
5. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.
6. Braak H, Tredici KD, Rüb U, de Vos RAI, Steur ENHJ, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
7. Brooks DJ. Imaging approaches to Parkinson disease. J Nucl Med 2010;51:596-609.
8. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
9. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 2000;23:34-44.
10. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET Study. Ann Neurol 2003;54:93-101.
11. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
12. Fahn S, and the Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252:IV37-IV42.
13. Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence od dopaminergic deficit (SWEDDs). Mov Disord 2007;22:2210-2215.
14. Marek K, Jennings D, Seibyl J. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDDs) in the ELLDOPA study. Neurology 2005;64(Suppl 1):S274.
15. Bain PG. Dystonic tremor presenting as parkinsonism: long-term follow-up of SWEDDs. Neurology 2009;72:1443-1445.
16. Silveira-Moriyama L, Schwingenschuh P, O'Donnell A, et al. Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). J Neurol Neurosurg Psychiatry 2009;80:744-748.
17. Doty RL. Olfaction in Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl):S225-S228.
18. Lim S, Lang AE. The nonmotor symptoms of Parkinson's disease-an overview. Mov Disord 2010;25(Suppl 1):S123-S130.
19. Santin R, Fonseca VF, Bleil CB, Rieder CRM, Hilbig A. Olfactory function and Parkinson's disease in Southern Brazil. Arq Neuropsiquiatr 2010;68:252-257.
20. Mian OS, Schneider SA, Schwingenschuh P, Bhatia KP, Day BL. Gait in SWEDDs patients: comparison with Parkinson's disease patients and healthy controls. Mov Disord 2011;26:1266-1273.